|
|
Volumn 176, Issue 8, 2002, Pages 361-362
|
|
Hepatitis C: Where are we at and where are we going?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTIVIRUS AGENT;
HEPATITIS C ANTIBODY;
RIBAVIRIN;
VACCINE;
AUSTRALIA;
COMMUNITY CARE;
DRUG EFFICACY;
DRUG USE;
EDITORIAL;
EPIDEMIC;
FINANCIAL MANAGEMENT;
HEALTH CARE;
HEALTH CARE AVAILABILITY;
HEALTH PROGRAM;
HEALTH SERVICE;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
IMMUNOPATHOGENESIS;
INFECTION PREVENTION;
LIVER FAILURE;
LIVER FIBROSIS;
NONHUMAN;
PRESCRIPTION;
PRISON;
VIRUS IDENTIFICATION;
|
|
EID: 0037090499
PISSN: 0025729X
EISSN: None
Source Type: Journal
DOI: 10.5694/j.1326-5377.2002.tb04454.x Document Type: Editorial |
|
Times cited : (7)
|
|
References (11)
|
